Larsson C, Stålhammar-Carlemalm M, Lindahl G
Department of Medical Microbiology, Lund University, Sweden.
Vaccine. 1999 Feb 5;17(5):454-8. doi: 10.1016/s0264-410x(98)00218-7.
Group B streptococcus (GBS), a bacterium with polysaccharide capsule, is the major cause of sepsis and meningitis in early infancy. Recent work has indicated that immunity to GBS infection can be elicited by the surface proteins Rib and alpha, either of which is expressed by most GBS strains causing invasive infections. Here we show that a bivalent vaccine, composed of purified Rib and alpha mixed with aluminum hydroxide (alum), an adjuvant accepted for human use, elicits an antibody response to each of the two antigens. Moreover, the bivalent vaccine was found to protect against experimental infection with GBS strains representing the four classical serotypes. Our results represent an encouraging step towards the development of a human GBS vaccine based on pure protein antigens.
B组链球菌（GBS）是一种带有多糖荚膜的细菌，是婴儿早期败血症和脑膜炎的主要病因。最近的研究表明，针对GBS感染的免疫力可由表面蛋白Rib和α引发，大多数引起侵袭性感染的GBS菌株都会表达这两种蛋白中的一种。在此我们表明，一种由纯化的Rib和α与氢氧化铝（明矾，一种被批准用于人类的佐剂）混合而成的二价疫苗，可引发针对这两种抗原中每一种的抗体反应。此外，发现该二价疫苗可预防由代表四种经典血清型的GBS菌株引起的实验性感染。我们的结果代表了基于纯蛋白抗原开发人类GBS疫苗的令人鼓舞的一步。
